379 related articles for article (PubMed ID: 33485960)
1. First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1.
Reck M; Ciuleanu TE; Lee JS; Schenker M; Audigier-Valette C; Zurawski B; Linardou H; Otterson GA; Salman P; Nishio M; de la Mora Jimenez E; Lesniewski-Kmak K; Albert I; Ahmed S; Syrigos K; Penrod JR; Yuan Y; Blum SI; Nathan FE; Sun X; Moreno-Koehler A; Taylor F; O'Byrne KJ
J Thorac Oncol; 2021 Apr; 16(4):665-676. PubMed ID: 33485960
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.
Kato K; Doki Y; Chau I; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Makino T; Blum Murphy M; Amaya-Chanaga C; Patel A; Hu N; Matsumura Y; Kitagawa Y; Ajani J
Cancer Med; 2024 May; 13(9):e7235. PubMed ID: 38716626
[TBL] [Abstract][Full Text] [Related]
3. PD-L1-negative Non-small-cell Lung Cancer Treated with Nivolumab Plus Ipilimumab during Maintenance Hemodialysis Results in Rapid Initial Progression Followed by a Long-lasting Response.
Yano S; Uematsu S; Kunimune N; Harima T; Yoshida Y; Takahashi S; Ito M; Sakamoto H; Nishizaka Y
Intern Med; 2024 Apr; 63(7):985-988. PubMed ID: 37558475
[TBL] [Abstract][Full Text] [Related]
4. Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score.
Galsky MD; Bajorin DF; Witjes JA; Gschwend JE; Tomita Y; Nasroulah F; Li J; Collette S; Valderrama BP; Grimm MO; Appleman L; Gravis G; Necchi A; Ye D; Stenner F; Wind-Rotolo M; Zhang J; Ünsal-Kaçmaz K
Eur Urol; 2023 May; 83(5):432-440. PubMed ID: 36868932
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.
Ikeda G; Miyakoshi J; Yamamoto S; Kato K
Future Oncol; 2024 Apr; 20(11):665-677. PubMed ID: 38126175
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.
Omuro A; Vlahovic G; Lim M; Sahebjam S; Baehring J; Cloughesy T; Voloschin A; Ramkissoon SH; Ligon KL; Latek R; Zwirtes R; Strauss L; Paliwal P; Harbison CT; Reardon DA; Sampson JH
Neuro Oncol; 2018 Apr; 20(5):674-686. PubMed ID: 29106665
[TBL] [Abstract][Full Text] [Related]
7. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer.
Feldman H; Sepesi B; Leung CH; Lin H; Weissferdt A; Pataer A; William WN; Walsh GL; Rice DC; Roth JA; Mehran RJ; Hofstetter WL; Antonoff MB; Rajaram R; Gibbons DL; Lee JJ; Heymach JV; Vaporciyan AA; Swisher SG; Cascone T
J Thorac Cardiovasc Surg; 2024 Apr; 167(4):1444-1453.e4. PubMed ID: 37816395
[TBL] [Abstract][Full Text] [Related]
8. Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer Perspective.
Qiao N; Insinga R; Burke T; Lopes G
Pharmacoecon Open; 2021 Dec; 5(4):765-778. PubMed ID: 34292540
[TBL] [Abstract][Full Text] [Related]
9. [History and Perspective of Chemotherapy in Advanced Esophageal Cancer].
Shiraishi K; Kato K
Gan To Kagaku Ryoho; 2024 Mar; 51(3):240-244. PubMed ID: 38494800
[TBL] [Abstract][Full Text] [Related]
10. Discussion to: Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer.
J Thorac Cardiovasc Surg; 2024 Apr; 167(4):1454-1455. PubMed ID: 38340115
[No Abstract] [Full Text] [Related]
11. Association of Remote Patient-Reported Outcomes and Step Counts With Hospitalization or Death Among Patients With Advanced Cancer Undergoing Chemotherapy: Secondary Analysis of the PROStep Randomized Trial.
Manz CR; Schriver E; Ferrell WJ; Williamson J; Wakim J; Khan N; Kopinsky M; Balachandran M; Chen J; Patel MS; Takvorian SU; Shulman LN; Bekelman JE; Barnett IJ; Parikh RB
J Med Internet Res; 2024 May; 26():e51059. PubMed ID: 38758583
[TBL] [Abstract][Full Text] [Related]
12. Assessing the impact of open-label designs in patient-reported outcomes: investigation in oncology clinical trials.
Lord-Bessen J; Signorovitch J; Yang M; Georgieva M; Roydhouse J
JNCI Cancer Spectr; 2023 Mar; 7(2):. PubMed ID: 36661326
[TBL] [Abstract][Full Text] [Related]
13. Autopsy case of meningoencephalitis induced by nivolumab and ipilimumab in a patient being treated for non-small cell lung cancer.
Shiraha K; Watanabe H; Fujiwara K; Goda M; Inoue T; Fujiwara M; Matsuoka S; Takigawa Y; Mitsumune S; Kudo K; Sato A; Sato K; Shinno Y; Shibayama T
Intern Med; 2024 Apr; ():. PubMed ID: 38631854
[TBL] [Abstract][Full Text] [Related]
14. Real-world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey.
Cheng LJ; Kim J; Mukherjee A; Milloy N; Unsworth M; Ng D
Int J Urol; 2024 May; ():. PubMed ID: 38787505
[TBL] [Abstract][Full Text] [Related]
15. Correction to: First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Jpn J Clin Oncol; 2024 May; ():. PubMed ID: 38774943
[No Abstract] [Full Text] [Related]
16. Successful mycophenolate mofetil treatment of a patient with severe steroid-refractory hepatitis evoked by nivolumab plus ipilimumab treatment for relapsed bladder cancer.
Omori G; Takada K; Murase K; Hayasaka N; Nakamura H; Iyama S; Ohnuma H; Miyanishi K; Fukuta F; Tanaka T; Masumori N; Kato J
Clin Case Rep; 2021 Feb; 9(2):654-659. PubMed ID: 33598220
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
Boyer M; Şendur MAN; Rodríguez-Abreu D; Park K; Lee DH; Çiçin I; Yumuk PF; Orlandi FJ; Leal TA; Molinier O; Soparattanapaisarn N; Langleben A; Califano R; Medgyasszay B; Hsia TC; Otterson GA; Xu L; Piperdi B; Samkari A; Reck M;
J Clin Oncol; 2021 Jul; 39(21):2327-2338. PubMed ID: 33513313
[TBL] [Abstract][Full Text] [Related]
18. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331
Spigel DR; Vicente D; Ciuleanu TE; Gettinger S; Peters S; Horn L; Audigier-Valette C; Pardo Aranda N; Juan-Vidal O; Cheng Y; Zhang H; Shi M; Luft A; Wolf J; Antonia S; Nakagawa K; Fairchild J; Baudelet C; Pandya D; Doshi P; Chang H; Reck M
Ann Oncol; 2021 May; 32(5):631-641. PubMed ID: 33539946
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Cascone T; William WN; Weissferdt A; Leung CH; Lin HY; Pataer A; Godoy MCB; Carter BW; Federico L; Reuben A; Khan MAW; Dejima H; Francisco-Cruz A; Parra ER; Solis LM; Fujimoto J; Tran HT; Kalhor N; Fossella FV; Mott FE; Tsao AS; Blumenschein G; Le X; Zhang J; Skoulidis F; Kurie JM; Altan M; Lu C; Glisson BS; Byers LA; Elamin YY; Mehran RJ; Rice DC; Walsh GL; Hofstetter WL; Roth JA; Antonoff MB; Kadara H; Haymaker C; Bernatchez C; Ajami NJ; Jenq RR; Sharma P; Allison JP; Futreal A; Wargo JA; Wistuba II; Swisher SG; Lee JJ; Gibbons DL; Vaporciyan AA; Heymach JV; Sepesi B
Nat Med; 2021 Mar; 27(3):504-514. PubMed ID: 33603241
[TBL] [Abstract][Full Text] [Related]
20. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Sezer A; Kilickap S; Gümüş M; Bondarenko I; Özgüroğlu M; Gogishvili M; Turk HM; Cicin I; Bentsion D; Gladkov O; Clingan P; Sriuranpong V; Rizvi N; Gao B; Li S; Lee S; McGuire K; Chen CI; Makharadze T; Paydas S; Nechaeva M; Seebach F; Weinreich DM; Yancopoulos GD; Gullo G; Lowy I; Rietschel P
Lancet; 2021 Feb; 397(10274):592-604. PubMed ID: 33581821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
